371 related articles for article (PubMed ID: 23136357)
1. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
2. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
Perry CM
Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
[TBL] [Abstract][Full Text] [Related]
3. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
[TBL] [Abstract][Full Text] [Related]
4. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
5. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment.
Manzardo C; Gatell JM
AIDS Rev; 2014; 16(1):35-42. PubMed ID: 24584107
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
Raffe S; Fisher M
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):427-35. PubMed ID: 25553805
[TBL] [Abstract][Full Text] [Related]
7. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
Lampiris HW
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):13-20. PubMed ID: 22149610
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
9. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Marchand C
Expert Opin Investig Drugs; 2012 Jul; 21(7):901-4. PubMed ID: 22571404
[TBL] [Abstract][Full Text] [Related]
10. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
11. Stribild: a review of component characteristics and combination drug efficacy.
Murrell DE; Moorman JP; Harirforoosh S
Eur Rev Med Pharmacol Sci; 2015; 19(5):904-14. PubMed ID: 25807445
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
[TBL] [Abstract][Full Text] [Related]
13. Single-tablet, once-daily treatment regimens for HIV.
Sawyer JR; Ma Q; Hsiao CB
Lancet Infect Dis; 2014 Apr; 14(4):265-7. PubMed ID: 24670622
[No Abstract] [Full Text] [Related]
14. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
Temesgen Z
Drugs Today (Barc); 2012 Dec; 48(12):765-71. PubMed ID: 23243633
[TBL] [Abstract][Full Text] [Related]
15. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
Pozniak A; Markowitz M; Mills A; Stellbrink HJ; Antela A; Domingo P; Girard PM; Henry K; Nguyen T; Piontkowsky D; Garner W; White K; Guyer B
Lancet Infect Dis; 2014 Jul; 14(7):590-9. PubMed ID: 24908550
[TBL] [Abstract][Full Text] [Related]
16. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
17. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
18. Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Prescrire Int; 2013 Oct; 22(142):233-5. PubMed ID: 24298581
[TBL] [Abstract][Full Text] [Related]
19. Single-tablet regimens in HIV: does it really make a difference?
Aldir I; Horta A; Serrado M
Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
